These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37620236)

  • 1. Biomarkers for osteoarthritis: Current status and future prospects.
    Mobasheri A; Thudium CS; Bay-Jensen AC; Maleitzke T; Geissler S; Duda GN; Winkler T
    Best Pract Res Clin Rheumatol; 2023 Jun; 37(2):101852. PubMed ID: 37620236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice?
    Mobasheri A; Bay-Jensen AC; Gualillo O; Larkin J; Levesque MC; Henrotin Y
    Best Pract Res Clin Rheumatol; 2017 Oct; 31(5):705-720. PubMed ID: 30509415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
    Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
    Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.
    Oo WM; Yu SP; Daniel MS; Hunter DJ
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):331-347. PubMed ID: 30415584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
    Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
    Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.
    Kraus VB; Blanco FJ; Englund M; Henrotin Y; Lohmander LS; Losina E; Önnerfjord P; Persiani S
    Osteoarthritis Cartilage; 2015 May; 23(5):686-97. PubMed ID: 25952342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of (osteo)arthritis.
    Mobasheri A; Henrotin Y
    Biomarkers; 2015; 20(8):513-8. PubMed ID: 26954784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current opinion: where are we in our understanding and treatment of osteoarthritis?
    Poole AR
    Swiss Med Wkly; 2016; 146():w14340. PubMed ID: 27463798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
    Kim H; Seo J; Lee Y; Park K; Perry TA; Arden NK; Mobasheri A; Choi H
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221085952. PubMed ID: 36504595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical monitoring in osteoarthritis: Biomarkers.
    Kraus VB; Karsdal MA
    Osteoarthritis Cartilage; 2022 Sep; 30(9):1159-1173. PubMed ID: 34536529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.
    Kraus VB; Burnett B; Coindreau J; Cottrell S; Eyre D; Gendreau M; Gardiner J; Garnero P; Hardin J; Henrotin Y; Heinegård D; Ko A; Lohmander LS; Matthews G; Menetski J; Moskowitz R; Persiani S; Poole AR; Rousseau JC; Todman M;
    Osteoarthritis Cartilage; 2011 May; 19(5):515-42. PubMed ID: 21396468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in understanding the phenotypes of osteoarthritis.
    Mobasheri A; Saarakkala S; Finnilä M; Karsdal MA; Bay-Jensen AC; van Spil WE
    F1000Res; 2019; 8():. PubMed ID: 31885861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine.
    Henrotin Y; Sanchez C; Cornet A; Van de Put J; Douette P; Gharbi M
    Biomarkers; 2015; 20(8):540-6. PubMed ID: 26954785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoarthritis--a case for personalized health care?
    Karsdal MA; Christiansen C; Ladel C; Henriksen K; Kraus VB; Bay-Jensen AC
    Osteoarthritis Cartilage; 2014 Jan; 22(1):7-16. PubMed ID: 24216058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapeutic Targets for Osteoarthritis Pain.
    Walsh DA; Stocks J
    SLAS Discov; 2017 Sep; 22(8):931-949. PubMed ID: 28683214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
    Sabha M; Siaton BC; Hochberg MC
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development.
    Bay-Jensen AC; Thudium CS; Gualillo O; Mobasheri A
    Drug Discov Today; 2018 Feb; 23(2):349-358. PubMed ID: 29038075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects of Disease-Modifying Osteoarthritis Drugs.
    Oo WM
    Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.
    Cho Y; Jeong S; Kim H; Kang D; Lee J; Kang SB; Kim JH
    Exp Mol Med; 2021 Nov; 53(11):1689-1696. PubMed ID: 34848838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for Therapies in Osteoarthritis.
    Ghouri A; Conaghan PG
    Calcif Tissue Int; 2021 Sep; 109(3):339-350. PubMed ID: 32055890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.